Does inhibition of 6-phosphofructo-2-kinase ( PFKFB3 ) suppress glucose metabolism and the growth of HER2+ breast cancer?
Taken together, these data support the potential clinical utility of PFKFB3 inhibitors as chemotherapeutic agents against HER2+ breast cancer.
Hypometabolic areas in the cerebral parenchyma are frequently associated to metastatic lesions in patients with small cell lung cancer. The selective brain PET/CT in these patients allows correct staging and early treatment of unsuspected metastasis.